---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Phototherapy"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Phototherapy. Topics: Narrowband UVB: guideline recommendations on monotherapy, dosing frequency, and preference over PUVA; Narrowband UVB efficacy: PASI 75 and clearance rates in pooled trials; Oral PUVA compared with narrowband UVB: efficacy, number of treatments, and adverse effects; Treatment burden: travel to a phototherapy center and home phototherapy; 3 further topics. 7 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/phototherapy"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Phototherapy

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Phototherapy

<a id="topic-2.2.2.1.2-1"></a>

### Narrowband UVB: guideline recommendations on monotherapy, dosing frequency, and preference over PUVA

> “NB-UVB phototherapy is recommended for adults with plaque psoriasis as monotherapy”
> “During the treatment phase, 3-times/wk dosing of NB-UVB phototherapy for adults with generalized plaque psoriasis is recommended”
> “Though less effective, NB-UVB is preferred to PUVA monotherapy for the treatment of psoriasis in adults because of enhanced safety, convenience, and cost savings”
> “Home NB-UVB phototherapy is recommended for appropriate patients with generalized plaque psoriasis as an alternative to in-office NB-UVB phototherapy”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-2"></a>

### Narrowband UVB efficacy: PASI 75 and clearance rates in pooled trials

> “Across these 9 studies, 62% of patients achieved PASI 75”
> “An average clearance rate of 68% was observed”
> “In a systematic review and meta-analysis of 8 trials, 70% of patients achieved PASI 75 with NB-UVB phototherapy”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-3"></a>

### Oral PUVA compared with narrowband UVB: efficacy, number of treatments, and adverse effects

> “Though more effective, oral PUVA causes a higher rate of adverse effects, with symptomatic erythema and blistering observed in 17% of patients versus in 7.8% with NB-UVB”
> “Fewer treatments were required to reach clearance with PUVA than with NB-UVB (17 vs 25), and there was a higher likelihood of remission 6 months following PUVA treatment than following NB-UVB treatment (odds ratio, 2.73; 95% confidence interval, 1.19-6.27)”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-4"></a>

### Treatment burden: travel to a phototherapy center and home phototherapy

> “For patients for whom travel to a phototherapy center is a limiting factor, home NB-UVB units should be considered.”
> “Of the individuals who received hospital-based phototherapy, 41.7% achieved PASI 75 after 46 treatments compared with 40.7% of those receiving home phototherapy.”
> “The burden of treatment was significantly lower, and patients were happier with their treatments when the UV light was delivered in the home phototherapy setting.”
> “To achieve maximal efficacy, treatment with targeted UVB phototherapy for adults with localized plaque psoriasis should be carried out 2-3 times/wk rather than once every 1-2 wk”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-5"></a>

### Phototherapy safety precautions: guideline recommendations

> “Long-term combination therapy with cyclosporine and NB-UVB phototherapy is not recommended for adults with generalized plaque psoriasis because of increased incidence of skin cancer”
> “NB-UVB should be used with caution in patients with a history of melanoma or multiple nonmelanoma skin cancers, history of arsenic intake, and/or prior exposure to ionizing radiation due to the potential risk of photocarcinogenesis”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-6"></a>

### Phototherapy use relative to other treatment types

> “The most frequently used phototherapy modality is UV-B, whereas methotrexate is the most commonly used oral agent.”

Source: [Armstrong et al. (2013d)](https://pubmed.ncbi.nlm.nih.gov/23945732/)

> “Of the patients lapsed and currently treated in this period, the numbers who received each treatment type were 156,409 (biologic), 222,657 (traditional oral systemic), 22,911 (phototherapy), and 293,511 (topical).”

Source: [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/)

<a id="topic-2.2.2.1.2-7"></a>

### Joint American Academy of Dermatology and National Psoriasis Foundation phototherapy guideline: scope and update of the 2010 guideline

> “Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy”
> “This section covers the use of phototherapy in the treatment of psoriasis in adults; psoriasis treatment in the pediatric population is addressed in the Joint American Academy of Dermatology–National Psoriasis Foundation Guidelines of Care for the Management and Treatment of Psoriasis in Pediatric Population (in preparation).”
> “was convened to update and expand on the previously published 2010 American Academy of Dermatology (AAD) psoriasis guideline”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
